Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.
Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.
复制标题
DOI：
10.1038/s41366-021-00804-7
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Koutroulis I
中科院分区：
文献类型：
--
作者：
Batabyal R;Freishtat N;Hill E;Rehman M;Freishtat R;Koutroulis I
COVID-19疫情已成为一场公共卫生危机，并对医疗系统造成重大负担。有潜在代谢功能障碍的患者，如2型糖尿病和肥胖症，患COVID-19并发症的风险更高，包括继发于免疫反应紊乱和细胞能量剥夺的多器官功能障碍。这些患者处于慢性炎症的基线状态，与对COVID-19严重免疫表现的易感性增加相关，这是由细胞缺氧环境和细胞因子风暴引发的。免疫细胞的代谢特征和能量产生的改变影响它们的活化，加剧了不平衡的免疫反应。关键的免疫代谢相互作用可能为开发有效的COVID-19治疗方法提供信息。新的治疗方法与再利用的药物，如PPAR激动剂，或新开发的分子，如阻断microRNA功能，已显示出有希望的结果。这些治疗，单独或组合，目标免疫和代谢途径，是理想的脓毒症COVID-19患者与潜在的代谢条件。
The COVID-19 pandemic has emerged as a public health crisis and has placed a significant burden on healthcare systems. Patients with underlying metabolic dysfunction, such as type 2 diabetes mellitus and obesity, are at a higher risk for COVID-19 complications, including multi-organ dysfunction, secondary to a deranged immune response, and cellular energy deprivation. These patients are at a baseline state of chronic inflammation associated with increased susceptibility to the severe immune manifestations of COVID-19, which are triggered by the cellular hypoxic environment and cytokine storm. The altered metabolic profile and energy generation of immune cells affect their activation, exacerbating the imbalanced immune response. Key immunometabolic interactions may inform the development of an efficacious treatment for COVID-19. Novel therapeutic approaches with repurposed drugs, such as PPAR agonists, or newly developed molecules such as the antagomirs, which block microRNA function, have shown promising results. Those treatments, alone or in combination, target both immune and metabolic pathways and are ideal for septic COVID-19 patients with an underlying metabolic condition.
登录
查看更多内容
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
影响因子：
8.2
作者：
Boutens L;Hooiveld GJ;Dhingra S;Cramer RA;Netea MG;Stienstra R
通讯作者：
Stienstra R
影响因子：
8.7
作者：
Dinarello CA
通讯作者：
Dinarello CA
DOI：
10.4049/jimmunol.1600820
发表时间：
2016-11-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Cho KW;Zamarron BF;Muir LA;Singer K;Porsche CE;DelProposto JB;Geletka L;Meyer KA;O'Rourke RW;Lumeng CN
通讯作者：
Lumeng CN
影响因子：
5.8
作者：
Bremer, Andrew A.;Devaraj, Sridevi;Jialal, Ishwarlal
通讯作者：
Jialal, Ishwarlal